A previous small-sample size study showed that the argatroban plus tissue-type plasminogen activator (tPA) is safe in patients with AIS due to proximal intracranial occlusion and may contribute to vascular recanalization than tPA alone (Barreto et al., 2012). Here, PLAT is linked to androgen insensitivity syndrome.